How Many Eye Injections Will I Need for a Retinal Vein Occlusion?
Eye Injections for a Blocked Retinal Vein at a Glance
Most of this treatment is calm and routine. A few changes are not. Call your eye doctor and ask for a same day slot if any of these happen, above all in the first days after a shot:
- Eye pain that gets worse instead of better.
- A sudden drop in vision, or sight that keeps fading.
- An eye that turns red and painful.
- A curtain or shadow moving across your sight.
- New floaters in a shower, or new flashing lights.
The drug label for these injections warns that an infection inside the eye (clinical: endophthalmitis) and retinal detachment can follow a shot into the eye.1 Both are rare. A same day call is what keeps a rare problem small.
Plan for a course, not a single shot, and plan for the first year to be the busiest. In a large study of routine care covering 22,365 branch and 18,064 central vein occlusion eyes, the average number of injections in year one was 6.9 for a branch blockage and 7.0 for a central one, falling to 3.7 and 3.9 by year five.2 Your own number sits somewhere in a wide spread around those averages. It is set by how your macula responds, not by a fixed package agreed in advance.
A vein occlusion is a blocked drain at the back of the eye, and fluid backs up into the macula, the small central patch you read and recognise faces with. Medication injected into the eye can help reduce that swelling.3 It goes in through a very fine needle, in a clinic room, in a few minutes. Guidance names these anti-VEGF injections as the first line of treatment for the swelling.4
This page explains what drives the number of injections, so the schedule stops feeling arbitrary. It cannot count your injections, promise you a number, or tell you when yours will stop. Those answers come from your scans, the type of blockage, and how the swelling behaves in the first few months. Bring the questions at the end of this page to your next visit.
Why One Injection Is Never the Whole Treatment
The drug does not unblock the vein. It works on the fluid that collects after the blockage. Medicine injected into the eye can help reduce the swelling of the macula.3 So the target is the fluid, not the clot, and that is why progress is measured in scans of macular thickness rather than in any attempt to reopen the vessel.
Each dose works for a limited stretch of weeks, then fades. Because swelling in the retina returns after the medicine wears off, injections must be taken regularly for the benefit to last.3 A repeat injection is the normal course of events, not a sign that the last one failed. The useful question at each visit is not whether you need another, but how far apart the doses can safely sit.
Three licensed medicines all start on a monthly rhythm for this condition. Aflibercept (Eylea) is FDA-approved for macular edema following retinal vein occlusion at 2 mg into the eye once every 4 weeks.1 Ranibizumab (Lucentis) is given at 0.5 mg into the eye once a month, about every 28 days.5 Faricimab carries a United States approval for this swelling at 6 mg into the eye every 4 weeks.6 Your doctor sets your actual schedule.
The Numbers Real Patients Get, Year by Year
The first twelve months carry the heaviest load, because the fluid is at its worst and the response is still being learned. Averages from routine care were 6.9 injections in year one for branch occlusion eyes and 7.0 for central occlusion eyes, alongside average vision gains of 11.5 and 9.7 letters at twelve months.2 In one randomised trial, people with a central or hemiretinal blockage were injected every 4 weeks through month six and gained about 19 letters on average.7 The front-loading is deliberate.
The load usually eases, but for many people it does not disappear. By year five in that same routine-care database, the average had fallen to 3.7 injections for branch and 3.9 for central occlusion eyes, while about 68 of every 100 branch eyes and 71 of every 100 central eyes still had at least one injection that year.2 Read those as two facts side by side: fewer visits than year one, and treatment that often continues.
Registries that follow people through ordinary clinic life give a running total rather than a yearly average.
| Type of blockage | Injections over 3 years | Clinic visits |
|---|---|---|
| Branch occlusion | 16 (median) | 24 |
| Central occlusion | 18 (median) | 26 |
The branch row comes from a registry study of 760 eyes: a median of 16 injections across 24 visits over three years, with an average vision change of a gain of 11 letters.8 The central row comes from the 257 of 527 eyes that completed 36 months: a median of 18 injections across 26 visits, with an average gain of 12 letters.9
A branch blockage floods one section of the retina, while a central blockage backs up the whole drain. The gap in treatment burden is real but smaller than most people expect. Year one averages differed by about one tenth of an injection between the two, and by year five the central group averaged only slightly more than the branch group.2 The bigger difference shows up in vision gained, not in visits attended.
Who Gets This Treatment, and Who Should Wait
Treatment is aimed at the swelling, not at the blockage itself. Guidance names anti-VEGF injections as the first line of treatment for the macular swelling associated with a retinal vein occlusion.4 Injections into the eye can help reduce that swelling.3 So the thing that triggers a course is what your scan shows in the macula, which is worth asking about plainly at your first visit.
Some situations mean the shot waits, and none of them mean treatment is off the table for good. The aflibercept label lists infection in or around the eye, active inflammation inside the eye, and known hypersensitivity to the drug as reasons the injection is contraindicated.1 The ranibizumab label names infections in or around the eye, and known hypersensitivity to that drug.5 Tell your clinic about any eye infection, a cold sore near the eye, or recent eye surgery before the appointment.
A macula that dries quickly and stays dry between visits is the strongest signal in your favour. In one long follow-up, swelling had settled without further injections in 17 of 34 people with a branch blockage and 14 of 32 with a central blockage after about four years, and the last injection had been given within the first two years for about 76 of every 100 branch and 71 of every 100 central occlusion patients.10 That is why the early appointments carry so much weight.
Fluid that returns promptly whenever the gap widens is the usual reason a course runs long. Among people whose swelling had not settled by the fourth year, the average was still 3.2 injections that year for a branch blockage and 5.9 for a central one.10 In routine care, most eyes were still receiving at least one injection in year five.2 Ask your retina doctor which pattern your own scans point toward.
The Visit Where Your Plan Is Set, and the Days After a Shot
The visit that sets your plan is mostly imaging and conversation. You will have a scan of the macula, a dilated look at the retina, and often a dye photograph that maps where blood flow has been lost. Vision loss or blurring in part or all of one eye is the symptom your doctor is trying to explain, and it can arrive suddenly or worsen over several hours or days.11 Ask what your macular thickness is today, and what number would count as a good response.
The appointment is short and the injection is a small part of it. Numbing drops or gel go in, then a cleaning solution, then a small holder keeps the lids apart. The shot itself is a second or two of pressure. Pressure inside the eye can rise within 60 minutes of an injection, which is why some clinics check it before you leave.1 Most people are out inside an hour.
Expect a gritty, scratchy eye for a few hours, from the cleaning solution rather than the needle. A red patch on the white of the eye is common and fades over days. Small dark specks can drift through your vision for a day or two. Discomfort that is easing is the normal pattern. The labels warn that infection inside the eye can follow an injection.1 Pain that worsens rather than settles, with vision falling, is the pattern clinics ask you to report the same day.
Arrange a lift home for your first injection until you know how your eye reacts, since the drops and cleaning solution can blur it for a few hours. Most people return to desk work the next day. Aftercare rules differ between clinics, including swimming, eye rubbing and makeup, so follow the written instructions your own unit gives you rather than general advice from a page like this one.
Ways the Number of Injections Can Come Down
The usual route to fewer injections is not stopping early, it is widening the interval in steps while the macula stays dry. Your doctor extends the gap, checks the scan, and pulls it back in if fluid reappears. For some people the gaps run out altogether: swelling had settled without further injections in about half of those followed for four years.10 Ask what has to hold steady before your gap widens.
Newer drugs in this field are aimed squarely at the visit count, though the labelled starting rhythm is still monthly. Faricimab is licensed in the United States for this swelling at 6 mg every 4 weeks.6 Guidance also reports that a higher-dose form of aflibercept, given every 8 weeks after three to five monthly starter doses, was non-inferior to the 2 mg dose given every 4 weeks.4 Whether either suits your eye is a question for your retina doctor.
A steroid implant treats the swelling through inflammation instead of the leak signal, and it lasts months rather than weeks. The dexamethasone implant holds 0.7 mg of steroid in a slow-release polymer and is indicated for macular swelling after a branch or central vein occlusion.12 In its main trials the implants were spaced about six months apart, with a gain of at least 15 letters in about 30 of every 100 people two months after the first implant.13 Fewer visits, different risks.
Skipping injections looks like the obvious way to cut the number down, and it is the one move that tends to add to it. Swelling returns after the medicine wears off, which is why injections are given regularly for the benefit to last.3 Breaks are common: about 26 of every 100 branch occlusion eyes in one three-year registry had a treatment gap longer than 180 days.8 Keeping the early appointments is the lever you fully control.
Risks, Cost and What the Injections Buy You
Each injection carries a small, real risk of infection inside the eye, and the number is worth knowing rather than guessing. A meta-analysis found infection after 197 of 350,535 injections, about 6 in every 10,000.14 Labels for these drugs warn of endophthalmitis and retinal detachment after injection into the eye.1 The risk sits with each visit rather than piling up in any simple way, and a same day call is what your clinic asks for if the eye turns painful.
Fewer visits are bought with two specific costs, both of which your doctor will weigh against your own eye. Over twelve months, cataract progressed in 90 of 302 eyes with their own lens that received two implants, against 5 of 88 sham-treated eyes, and a pressure rise of at least 10 mmHg occurred in about 13 of every 100 eyes after the first implant.13 The label warns that steroid use in the eye may produce cataract, raised pressure and glaucoma.12
Averages describe groups, and your own result can land either side of them. In routine care, average gains were 11.5 letters for branch and 9.7 letters for central occlusion eyes at twelve months, easing to 8.2 and 5.3 letters by month sixty, and eyes that received more injections gained more on average.2 That last point is the practical one: the visits are not busywork, and attendance tracks with the result.
The real burden is often travel, time off work and a driver, not only the copay. Ask which drug your plan covers, what the charge per injection is, and whether a patient assistance programme applies. Bevacizumab is used off-label in the eye and is usually the lower-cost choice. In one randomised trial it was noninferior to aflibercept for vision at six months in central and hemiretinal blockages.7 Raise cost early, because it shapes which drug is chosen.
Watching Your Own Vision and Knowing When to Call
A home check takes ten seconds. Cover one eye, look at a door frame or a grid on the fridge, then swap eyes, and watch for new bends, gaps or a fresh smudge. Blurring or loss of vision in part or all of one eye is the change that matters, and it can arrive suddenly or build over hours or days.11 Home checks do not replace scans. They give you a reason to phone sooner.
Call the clinic rather than waiting for your scheduled slot if your vision drops noticeably, if the eye becomes red and painful, if a shadow crosses your sight, or if new floaters or flashes arrive. In more severe central blockages there can be pain and pressure in the affected eye.11 Most of these calls end in reassurance, and the few that do not are exactly the ones worth making.
Questions People Ask About the Number of Injections
Probably not, though nobody can promise a stopping date. Treatment usually thins out rather than ending on a fixed day. Swelling had settled without further injections in 17 of 34 people with a branch blockage and 14 of 32 with a central blockage followed for about four years, while the rest still needed treatment.10 In a larger routine-care database, most eyes still received at least one injection in year five.2 Ask which pattern your scans suggest.
Because the injection count follows the fluid, not the label on the diagnosis. Your doctor is watching how much fluid your macula holds and how fast it comes back once a dose wears off, and two eyes with the same diagnosis can behave quite differently on that measure. A year-one average of about 7 injections describes a group, not any single eye.2 Comparing your total with someone else's tells you little about your own outlook.
Partly, and it is a fair thing to raise. Clinics can often move an appointment by days, and the interval itself widens over time when the macula stays dry. What does not work is stretching the early gaps to suit a diary. Injections have to be taken regularly for the benefit to last, because swelling returns as the medicine wears off.3 Tell your clinic about travel or shift work early, so the plan is built around it.
Fluid can rebuild without pain to warn you. Breaks are common in real life. About 26 of every 100 eyes in one three-year registry had a treatment break longer than 180 days.8 In routine care, eyes that received more injections gained more vision on average.2 If that is you, book a scan rather than writing the eye off. Your doctor will judge what is still worth doing from the current picture.
Long courses are ordinary rather than alarming, and no fixed limit is set in advance. Registry patients received a median of 18 injections over three years for a central blockage9 and 16 for a branch blockage.8 The risk sits with each injection rather than accumulating in any simple way. Infection inside the eye occurred after about 6 in every 10,000 injections in a meta-analysis.14 Your doctor checks pressure, the lens and the retina as the course goes on.
No. Returning fluid is the expected behaviour of this condition between doses, which is why the schedule exists at all. Swelling returns after the medicine wears off, so injections are given regularly for the benefit to hold.3 A rebound after a widened gap usually means the interval was stretched a little too far, and the answer is to pull it back in rather than to abandon the drug.
More Questions About Cost, Timing and Stopping Treatment
No drug guarantees a lower count for an individual eye, though some are designed for longer gaps. Guidance reports that a higher-dose aflibercept regimen given every 8 weeks after three to five monthly doses was non-inferior to 2 mg every 4 weeks.4 Faricimab is licensed in the United States for this swelling on a 4-weekly schedule.6 Ask your retina doctor which option fits your scans, your insurance and your travel.
Sometimes, and it is a reasonable question if travel is the obstacle. In the implant trials, treatments were spaced about six months apart and about 30 of every 100 people gained at least 15 letters two months after the first implant.13 The trade is specific rather than vague: cataract progressed in 90 of 302 eyes with their own lens that received two implants, against 5 of 88 sham-treated eyes.13 Ask whether that trade suits your eye.
Your doctor stops when the macula stays dry through progressively longer gaps, not on a set date or a set number. In one long follow-up, the last injection had been given within the first two years for about 76 of every 100 branch and 71 of every 100 central occlusion patients.10 Ask what interval you would need to reach before treatment pauses, and what would bring you back. A pause is usually a monitored pause, with scans continuing.
That depends on your insurance, the drug chosen and how many injections your eye needs, so the clinic is the only place to get a real figure. Ask for the charge per injection, the coverage rules for each drug, and whether assistance programmes apply. Bevacizumab, used off-label in the eye, is usually the lower-cost option: in one randomised trial it was noninferior to aflibercept for vision at six months.7 Ask before the first injection, not after.
Take these to your next appointment and write the answers down.
- Is my blockage the branch type or the central type, and how does that change my schedule?
- How many injections should I plan for before we judge how my eye is responding?
- What is my macular thickness today, and what number are we aiming for?
- What has to hold steady before you widen the gap between injections?
- Which drug are you starting me on, and what does my plan cover?
- Would a steroid implant ever suit my eye, and what would it cost me in risk?
- Who do I call after hours if my vision drops or the eye becomes painful?
- Which doctor is tracking my blood pressure and blood sugar alongside this treatment?
- US Food and Drug Administration prescribing information via DailyMed (2024). EYLEA (aflibercept) injection prescribing information, revised 10/2024.
- Ophthalmology Retina (PMID 40441380) (2025). Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database.
- American Academy of Ophthalmology (EyeSmart) (2025). What Is Branch Retinal Vein Occlusion (BRVO)?.
- American Academy of Ophthalmology (2024). Retinal Vein Occlusions Preferred Practice Pattern.
- US Food and Drug Administration prescribing information via DailyMed (2024). LUCENTIS (ranibizumab) injection prescribing information, revised 2/2024.
- US Food and Drug Administration prescribing information via DailyMed (2026). VABYSMO (faricimab-svoa) injection prescribing information, revised 4/2026.
- JAMA (PMID 28492910) (2017). Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
- Ophthalmology Retina (PMID 38641007) (2024). Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!.
- Ophthalmology Retina (PMID 36371040) (2022). Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.
- Ophthalmology (PMID 24112944) (2014). Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
- American Academy of Ophthalmology (EyeSmart) (2025). What Is Central Retinal Vein Occlusion (CRVO)?.
- US Food and Drug Administration prescribing information via DailyMed (2026). OZURDEX (dexamethasone intravitreal implant) prescribing information, revised 3/2026.
- Ophthalmology (GENEVA study group, PMID 21764136) (2011). Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results.
- Ophthalmic Surgery, Lasers & Imaging Retina (PMID 24635156) (2014). Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.